SEC-sourced researchBeta

RARE

Ultragenyx Pharmaceutical Inc.

US markets

Data passport

CIK: 0001515673
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 17, 2026
SEC registry record: Operating company

Last updated: Oct 7, 2026, 3:00 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

RARE · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	434,000,000.0000	Feb 18, 2026
December 2024	560,000,000.0000	Feb 18, 2026
December 2025	673,000,000.0000	Feb 18, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	673,000,000.0000	-575,000,000.0000	-466,000,000.0000	1,532,000,000.0000	1,605,000,000.0000	Feb 18, 2026
December 2024	560,000,000.0000	-569,000,000.0000	-414,000,000.0000	1,503,000,000.0000	1,241,000,000.0000	Feb 18, 2026
December 2023	434,000,000.0000	-607,000,000.0000	-475,000,000.0000	—	—	Feb 18, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$673M	December 2025	Feb 18, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$560M	December 2024	Feb 18, 2026	10-K
Net incomeNetIncomeLoss	-$575M	December 2025	Feb 18, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$466M	December 2025	Feb 18, 2026	10-K
Total assetsAssets	$1.53B	December 2025	Feb 18, 2026	10-K
Total liabilitiesLiabilities	$1.61B	December 2025	Feb 18, 2026	10-K

New filings

Explore methodology ↗